ZUG, Switzerland--(BUSINESS WIRE)--Swiss pharmaceutical company Primex Pharmaceuticals AG announces the appointment of Ernesto Alegria as Chief Financial Officer. On August 13th, 2016, he joined Primex Pharmaceuticals’ Executive Management Team.
Most recently, Ernesto Alegria worked for Acino Group as Group CFO. His responsibilities included delisting the company from the Swiss Stock Exchange, a number of M&A transactions and developing Acino Group into a fast growing mid-size pharmaceutical company.
Prior to Acino, Mr. Alegria was Head of Business Controlling and Finance for the emerging markets of Takeda Pharmaceuticals International GmbH. Previously, he held senior financial and commercial roles with Nycomed and Norske Skog.
This follows the announcement in February 2016, that Primex Pharmaceuticals had acquired the global rights for an advanced oral pharmaceutical candidate for pediatric anesthesiology developed by Advicenne. With this acquisition, Primex Pharmaceuticals expanded its portfolio with a unique product that will be distributed through Primex’s existing and new partners. The market potential is evaluated as hundreds of millions of euros.
PANU PAAPPANEN, Chairman of the Board and Owner, commented: "Mr. Alegria has gained considerable relevant experience in the pharmaceutical industry. His strong financial control, market knowledge and transaction experience will be a considerable asset for Primex.”
KARI SARVANTO, President and Co-Founder of Primex Group, added: “I am delighted that we can attract a highly talented professional as Ernesto Alegria to our team to help us build sustainable growth.”
About Primex Pharmaceuticals
Primex Pharmaceuticals is a fast growing global specialty company spearheading a new lean pharmaceutical business model.
Primex aims to become the leading global innovative Anesthesia company helping patients undergo a wide range of medical procedures. With a portfolio of strong, trusted anesthesia products including Recofol N (propofol) acquired from Bayer, and the recent acquisition of a novel, oral solution pharmaceutical candidate for pediatric anesthesiology from Advicenne, Primex Pharmaceuticals will continue to identify and acquire new medications that complete the ‘Triad of Anesthesia’.
Primex Pharmaceuticals' global partner network operates in over 40 countries and reaches a population of nearly one billion. The company is headquartered in Zug, Switzerland; all Primex products are manufactured in the EU. Primex Pharmaceuticals has proven underlying business operations and historically strong revenue growth.
See more at www.Primexpharma.com
